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Introduction
Epithelial ovarian cancer (EOC) remains one of the leading causes of death in gynaecological malignancies in developed countries [1] [2] [3] [4] . The initial symptoms of ovarian cancer are often ambiguous, therefore it goes undiagnosed until after the disease is far advanced and has spread throughout the abdomen or to distant organs 5, 6 . Steroid hormone receptors expression in epithelial ovarian cancers have been proposed to have therapeutic and prognostic relevance, as is the case in breast cancers 7 . The determination of tumour characteristics such as age, International Federation of Gynaecology and Obstetrics (FIGO) stage, grade and histological subtypes has been associated with clinical behaviour and impact on treatment and prognosis but have been found to be limited 8 . Among the biological parameters proposed as possible prognostic factors in ovarian cancer, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-type 2 (HER-2/neu) have been tested as potential biomarkers that guide individualized treatment of the cancer 5, 6, 9 . Epithelial ovarian carcinoma results from repeated ovulations, where the cumulative effects of each minor trauma on the ovarian epithelium can lead to malignant transformation 10 . PR has been observed to predict better prognosis because of its protection against ovarian carcinoma development 11,12 . On the other hand, overexpression of ER has been found to be associated with poor prognosis due to its contribution to initiation and/or promotion of ovarian carcinogenesis 10,13 . The HER-2/neu has been shown to be over-expressed in approximately 20-30% of EOC with associated poor prognosis [14] [15] [16] .
Triple negative epithelial ovarian cancer (TNEOC) cases have been found to be more aggressive and display a worse prognosis than non-TNEOC cases 17 . This was similarly observed in the studies of triple negative breast cancer 18, 19 . This study was designed to determine the pattern of TNEOC among indigenous African women and correlate it with clinicopathological parameters.
Methods

Patient selection
We performed a retrospective review of ER, PR and HER-2/neu expression in 90 patients with histologically diagnosed epithelial ovarian cancer seen at the University College Hospital, Ibadan, Nigeria between January 2006 and December 2012. Non-epithelial primary ovarian cancers and metastatic cancers in the ovary were not included in this study. The demographic data and clinical history of these cases were obtained from the case notes, surgical daybooks, surgical pathology request forms, post-mortem records and Cancer Registry data. Formalin-fixed paraffin-embedded tissue blocks of histologically diagnosed solid EOC between January 2006 and December 2012 were retrieved and used for the study. The microscopic grading (three-grade system) of Shimizu and Silverberg was used, which assesses architectural pattern, nuclear pleomorphism and mitotic activity 20 . All histological classification of the EOC was based on the 2013 World Health Organisation (WHO) classification of ovarian tumours 21 . The FIGO staging of the cases used for this study was extracted from the case notes of the patients.
Ethics
The ethical clearance for this study was obtained from the Joint University of Ibadan/University College Hospital Ethical Review Committee (approval number UI/EC/13/0050) according to the Declaration of Helsinki.
Immunohistochemistry
The immunostaining procedure for HER-2/neu was carried out in accordance with the previously published article 22 . For the immunostaining procedure, three sections each for ER, PR and HER-2/neu at 5µm were cut from each of the paraffin-embedded tissue blocks after deparaffinization in xylene (two aliquots for five minutes each with the xylene covering the slide entirely). The sections were then rehydrated in graded alcohol concentrations (two aliquots each of 100% and 95% each and a single aliquot of 70%) in 250ml couplin jars. The antibodies used were monoclonal mouse anti-human ERα (Dako USA; clone ID5) and monoclonal mouse anti-human PR (Dako USA; clone PgR636) which identify the ER and PR nuclear protein antigens. The primary antibody used for HER-2/neu antigen was polyclonal rabbit anti-human C-erbB-2 (MBO/TEG, Dako USA, 1:800). The tissue sections were immersed in EDTA buffer (pH 9.0) for ER, citrate buffer (pH 6.0) for PR and in 1M Tris buffer (pH 9.0) for HER-2/neu. These slides were then incubated at room temperature for 20 minutes with primary monoclonal antibodies against ER (Dako USA, clone 1D5; 1:50), PR (Dako USA, clone PgR636; 1:50) and polyclonal rabbit anti-human C-erbB-2 (MBO/TEG, Dako USA, 1:800) followed by incubation in biotin-labelled secondary antibodies, polyclonal goat anti-mouse antibody for both ER and PR, (Dako USA, REF: K0675, LOT: 10081219) and polyclonal goat anti-rabbit antibody for HER-2/neu, (kitR, K5001, Dako Denmark) for 20 minutes and streptavidin-peroxidase complex (Dako USA, REF: K0675, LOT: 10084687) for another twenty minutes. The antigen-antibody complex was precipitated with di-aminobenzidine (DAB) for light microscopy with DAB substrate and DAB chromogen in the ratio of 1ml to 1 drop respectively. This was thereafter counterstained in Mayer's haematoxylin (Dako USA). Dehydration of the sections was performed in ascending grades of alcohol and cleared in xylene. The slides were coversliped with DPX mountant. Known cases of breast cancer with positive reactions for ER, PR and HER-2/neu were used as a positive control. Negative controls were cases of tumour sections that were pretreated in Tris but without primary antibody immunostaining. All slides were reviewed independently by the three of the authors and cases with discordant scores were re-evaluated to have a consensus score. Grading of nuclear ER and PR staining was performed using an immunoreactive H-scoring system {none= 0 (negative); 1-25%=1+ (weak); 26-50%=2+ (moderate); >50%=3+(strong)} 11 . HER-2/neu membrane staining was graded in according to the Hercep Test protocol system as 0, 1+, 2+ or 3+. Samples scored as 0 or 1+ were considered negative for HER-2/neu overexpression, 2+ was weakly positive and 3+ was strongly positive 22, 23 . Photomicrographs of the specimens were taken using Olympus digital camera, DP 21 at 400X magnification (Figure 1 ).
Statistical analysis
The data obtained were subjected to statistical analysis using Statistical Package for Social Sciences (SPSS) version 20. Statistical analysis was used to evaluate statistical associations between TNEOC and clinicopathological parameters i.e. age, FIGO stage grade, and histological subtypes. Continuous variables were compared using the student's T test and categorical variables were compared using the chi-square test, with the level of significance set at p <0.05. Thirty-eight (42.2%) of the 90 epithelial ovarian cancers (EOC) were negative for ER, PR and HER-2/neu expression (Figure 1 ). There was no significant association between triple-negative EOC and age (p = 0.218), FIGO stage (p = 0.425) and histological grade (p= 0.269). There were more TNEOC cases seen in patients older than 40 years than those below 40 years of age. Of 38 cases of TNEOC, 21 (55.3%) were found in the early stage (FIGO stage I and II) of epithelial ovarian cancer and 17 (44.7%) were at the advanced stage.
Results
However, sixteen (66.7%) of the 24 mucinous carcinomas were triple-negative, while only 21 (33.3%) of the 63 serous carcinomas were triple-negative and one (50%) of the two endometrioid carcinomas was triple-negative (Table 1) . There was therefore a significant association between triple-negative tumours and histological subtypes of EOC (p = 0.034). 
Discussion
A subgroup of epithelial ovarian cancer that is negative for ER, PR and HER-2/neu expression has been identified among indigenous African women. This subgroup is known as triple negative epithelial ovarian cancer (TNEOC). According to ER, PR, and HER-2/neu expressions, a breast cancer subtype known as triple negative breast cancer (TNBC) has been identified 24 .
In our study, triple negative tumours accounted for 42.2% of EOC. This value contrasts with the results of other studies 17, 25 and compares with the results of previous study 26 . A significant percentage (66.7%) of mucinous carcinoma were negative for ER, PR and HER-2/neu and this was statistically significant (p=0.034). This finding contrasts what was found from previous studies where there was no significant association between the TNEOC and histological subtypes 17, 25, 26 . No significant association was also found between the TNEOC and histological grade unlike what was observed by Liu et al. 17 and de Toledo et al. 26 where TNEOC was significantly correlated with histological grade. There was no significant association between TNEOC and age and FIGO stage compared to the findings of other studies 17, 25, 26 .
Our findings were comparable with what was found by Huo et al. in the population differences in breast cancer where triple negativity was predominant (27%) 19 . In view of the fact that triplenegative breast cancers are more often seen in black Africans and African-Americans and are associated with a poorer prognosis than non-triple-negative breast cancers, further studies of TNEOC in different environments are required.
Conclusions
A subtype of epithelial ovarian cancer that is negative for ER, PR and HER-2/neu has been discovered in Nigeria. Its (TNEOC) expression is high and is comparable to the triple negative breast cancer subtype seen in people of African ancestry. Future study of TNEOC in a large sample size should be considered.
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